{"id":"W4362545300","doi":"10.1158/1538-7445.am2023-5071","title":"Abstract 5071: Olverembatinib (HQP1351) enhances antitumor effects of immunotherapy in renal cell carcinoma (RCC)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Axitinib; Cancer research; Immunotherapy; Lenvatinib; Medicine; Tumor microenvironment; Cancer immunotherapy; Cancer; Pharmacology; Sorafenib; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001447112,0.0003692896,0.0007667928,0.0002251903,0.0001585343,0.000316255,0.0002779562,0.0003790247,0.00349616],"category_scores_gemma":[0.0001155302,0.0001045472,0.0003250882,0.0002775765,0.0001812362,0.0002642517,0.0001514115,0.0009019665,0.0005995439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003145276,"about_ca_system_score_gemma":0.000369738,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007501199,"about_ca_topic_score_gemma":0.001108459,"domain_scores_codex":[0.9998228,0.00002431015,0.00001635543,0.0000344267,0.00004180795,0.0000603901],"domain_scores_gemma":[0.9999524,0.000006719584,0.000008234946,0.000005625367,0.000006152644,0.00002084112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003494839,0.001862605,0.000728797,0.0002827675,0.00006293602,0.0001953115,0.00004261073,0.0004779075,0.9602844,0.0002156983,0.00131688,0.03103533],"study_design_scores_gemma":[0.001597451,0.02126076,0.01286587,0.00001543453,0.0001269634,0.00137522,0.0000619955,0.002229971,0.9531809,0.00009466031,0.007164318,0.00002637866],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.9945825,0.001920475,0.0004888524,0.000125385,0.00008680231,0.00007458944,0.0004962146,0.0001823517,0.002042906],"genre_scores_gemma":[0.9969574,0.0004714496,0.0004055912,0.00006634039,0.00001294146,0.00003152029,0.0007542481,0.00001054699,0.001289966],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.00349616,"threshold_uncertainty_score":0.01169586,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06318448062453177,"score_gpt":0.3873964400267268,"score_spread":0.324211959402195,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}